👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

GSK herpes vaccine fails in clinical trial

Published 11/09/2024, 09:33
© Reuters.  GSK herpes vaccine fails in clinical trial
UK100
-
GSK
-
GSK
-

Proactive Investors - Shares in GSK PLC (LON:GSK) fell over 1% after the drug maker said it would abandon further trials for a potential herpes vaccine after disappointing results from its clinical trials so far.

The FTSE 100 group said data from the phase II part of a proof-of-concept study of the vaccine candidate showed the drug, known as GSK3943104, showed it "did not meet the study's primary efficacy objective".

It therefore will not move the vaccine candidate into phase III studies.

As no safety concerns were observed, the clinical trial, known as TH HSV REC-003, will continue in order to generate follow-up data that could offer valuable insights into recurrent genital herpes, GSK said.

"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed," the company added.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.